EUCTR2006-004033-15-NLActive, not recruitingPhase 1
A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400mcg administered once-daily in the morning via DISKUS™ dry-powder inhaler) compared with salmeterol (50mcg administered twice-daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD.
GlaxoSmithKline Research and Development Limited0 sites0 target enrollmentStarted: September 28, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Subjects who give their signed written informed consent to participate.
- •2. Male subjects or female subjects of non child bearing potential (i.e. post-menopausal or surgically sterile) =40 years of age at screening (Visit 1).
- •Post-menopausal females are defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However if indicated this should be confirmed by estradiol and FSH levels consistent with menopause (according to laboratory ranges) at screening (Visit 1).
- •Surgically sterile females are defined as those with a documented (medical report verification) hysterectomy and/or bilateral oophorectomy or Tubal Ligation
- •3. COPD Diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society [Celli, 2004]:
- •COPD is a preventable and treatable disease characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
- •4. Tobacco Use: Subjects with a current or prior history of >10 pack-years of cigarette smoking at screening (Visit 1).
- •5. Severity of Disease:
- •Subjects who conform to the GOLD severity classification for Stage II disease in terms of post-bronchodilator spirometry (either confirmed within 3 months of Screening Visit 1 or at Screening Visit 1) :
- •Subjects with a measured post-salbutamol FEV1/FVC ratio of =0.70
- •Subjects with a measured post-salbutamol FEV1?50% and<80% of predicted normal according to Crapo et al. [Crapo, 1981]
- •A correction factor of 0.88 will be used in this study to determine Crapo-predicted values of FEV1 for people of African ethnic origin [American Thoracic Society, 1991].
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Women who are pregnant or lactating or of child bearing potential.
- •2. Primary diagnosis of asthma. (Subjects with a prior history of asthma are eligible if COPD is currently their primary diagnosis).
- •3. a-1 antitrypsin deficiency as the underlying cause of COPD.
- •4. Active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease or other active pulmonary disease.
- •5. Lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
- •6. Positive Hepatitis B surface antigen or positive hepatitis C antibody pre-study or at Screening (Visit 1).
- •7. Chest X-ray (or CT scan), which reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at screening if a chest X-ray or CT scan is not available within the 6 months preceding Screening (Visit 1).
- •8. Poorly controlled COPD.
- •9. Clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine or haematological abnormalities that are uncontrolled.
- •10. Blood potassium level <3.0mmol/L at Screening (Visit 1)
- •11. A mean QTc(B) value at screening (Visit 1) >430 msec (male) / >450 msec (female), a mean PR interval outside the range 120-210 msec or an ECG that is not suitable for QT measurements (e.g. poorly defined termination of the T wave).
- •12. Any of the following abnormalities, identified on any of the resting 12-lead ECG at screening (Visit 1):
- •Ventricular rate <40 beats per minute PR interval >240 msec
- •Evidence of second or third degree atrioventricular (AV) block
- •Pathological Q waves (>40 msec depth greater than 0.04–0.05 mV)
- •Evidence of frequent supraventricular or ventricular ectopics, or arrhythmias
- •ST-T wave abnormalities, with the exception of early repolarisation which is acceptable
- •Right or left complete bundle branch block
- •13. History of elevated supine blood pressure or a mean supine blood pressure equal to or higher than 150/90 mmHg at screening (Visit 1).
- •14. Mean heart rate outside the range 40 – 90 beats per minute (bpm) at screening (Visit 1).
- •15. Carcinoma that has not been in complete remission for at least 5 years.
- •Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma would not be excluded if the subject was considered cured in less than 5 years since diagnosis.
- •16. History of hypersensitivity to any beta-agonist or to ipratropium bromide. In addition patients with a history of milk protein allergy would also be excluded.
- •17. Known or suspected history of alcohol or drug abuse within the last 2 years.
- •18. Unable to withhold their rescue medication for the 6 hour period required prior to spirometry testing at each study visit would be ineligible for the study.
- •19. The following medications listed below must not have been used prior to Screening (Visit 1) for the required interval indicated and not taken during the Run-in:
- •MedicationTime Interval
- •Inhaled steroids at doses of > 1000mcg/day FP equivalent6 weeks
- •Oral corticosteroids8 weeks
- •Theophyllines48 hours
- •Salmeterol and other long-acting beta-agonists48 hours
- •Oral leukotriene inhibitors 48 hours
- •Inhaled sodium cromoglycate or nedocromil sodium48 hours
- •Ipratropium/albuterol combination product6 hours
- •Inhaled short acting beta-agonists6 hours
- •Oral beta2-agonists48 hours
- •Inhaled LABA/ICS combination products 48 hours
- •Tiotropium2 weeks
- •Systemic, parenteral or de
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDpolycystic kidney diseaseMedDRA version: 8.1Level: LLTClassification code 10011771Term: Cystic kidney diseaseEUCTR2006-001485-16-FRovartis Pharma GmbH300
Active, not recruiting
Phase 1
immunoglobulin infusion as adjuvant therapy in patients with Pemphigus VulgarisEUCTR2013-000211-24-DERuprecht-Karls-University Heidelberg10
Active, not recruiting
Not Applicable
A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDEUCTR2006-001485-16-ATovartis Pharma GmbH300
Recruiting
Not Applicable
Evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg compared with each monotherapyEndocrine, nutritional and metabolic diseaseKCT0001405G Life Sciences285
Active, not recruiting
Phase 2
A study of JNJ-64042056 in participants with preclinical Alzheimer's diseasePreclinical Alzheimer’s DiseaseNervous System DiseasesISRCTN78730935Janssen-Cilag International NV498